AbbVie Inc. $ABBV Shares Sold by American Century Companies Inc.

American Century Companies Inc. decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,316,791 shares of the company’s stock after selling 112,023 shares during the period. AbbVie makes up about 0.4% of American Century Companies Inc.’s holdings, making the stock its 20th biggest position. American Century Companies Inc.’s holdings in AbbVie were worth $767,971,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Madison Wealth Partners Inc purchased a new stake in shares of AbbVie during the 3rd quarter worth $236,000. Huntington National Bank boosted its holdings in AbbVie by 3.6% during the third quarter. Huntington National Bank now owns 699,318 shares of the company’s stock worth $161,920,000 after buying an additional 24,310 shares in the last quarter. Compass Capital Corp MA ADV grew its position in AbbVie by 6.0% during the third quarter. Compass Capital Corp MA ADV now owns 1,229 shares of the company’s stock worth $269,000 after buying an additional 70 shares during the period. Mosaic Family Wealth Partners LLC increased its holdings in AbbVie by 14.2% in the third quarter. Mosaic Family Wealth Partners LLC now owns 5,847 shares of the company’s stock valued at $1,305,000 after buying an additional 729 shares in the last quarter. Finally, Abacus Wealth Partners LLC lifted its position in shares of AbbVie by 4.4% during the 3rd quarter. Abacus Wealth Partners LLC now owns 4,865 shares of the company’s stock valued at $1,126,000 after acquiring an additional 204 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.25% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Scotiabank assumed coverage on AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Royal Bank Of Canada began coverage on AbbVie in a research report on Tuesday. They issued an “outperform” rating and a $260.00 price target for the company. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Citigroup decreased their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Finally, Piper Sandler raised their target price on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Trading Up 3.1%

NYSE ABBV opened at $231.69 on Friday. The business’s 50-day moving average price is $224.34 and its 200 day moving average price is $222.94. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a market capitalization of $409.66 billion, a PE ratio of 98.17, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio is 293.22%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RBC Capital Markets initiated coverage with an Outperform rating and a $260 price target, arguing AbbVie’s growth is durable and the shares have been punished by short‑term competitive concerns — a bullish analyst catalyst that likely supported buying interest. RBC Launches AbbVie Coverage
• Positive Sentiment: The U.S. Justice Department publicly backed AbbVie’s challenge to Colorado’s 340B guidance, giving the company federal support in a case that could affect how discounts are applied and future margin outcomes in that program. DOJ backs AbbVie in 340B fight
• Positive Sentiment: Federal agencies also supported AbbVie’s position in Colorado in separate coverage, reinforcing regulatory/legal momentum in the company’s favor that could protect 340B economics if courts rule similarly. Feds back AbbVie in Colorado 340B fight
• Positive Sentiment: AbbVie received FDA approval for a first‑in‑class, all‑oral fixed‑duration regimen for untreated CLL and announced a $380M U.S. manufacturing buildout to support neuroscience and obesity programs — both add to medium‑term revenue and capacity upside. AbbVie’s CLL Breakthrough And US$380m Build Out
• Positive Sentiment: AbbVie reported fresh real‑world/post‑marketing data updates for upadacitinib (Rinvoq) in teens with eczema — data investors should watch for uptake and label/market expansion implications for a key growth franchise. Upadacitinib Study in Teens
• Neutral Sentiment: Zacks highlights AbbVie as a top long‑term value stock based on style scores — a framing piece that supports a buy thesis but doesn’t present new company‑specific catalysts. Why AbbVie is a Top Value Stock
• Neutral Sentiment: Dividend and longer‑term outlook pieces (Seeking Alpha / Motley Fool) reiterate AbbVie’s income profile and buy‑and‑hold case, helpful context for income investors but unlikely to trigger near‑term moves alone. Health Care Q4 Dividend Roundup
• Negative Sentiment: A Tennessee court rejected AbbVie’s challenge to that state’s contract‑pharmacy law, a loss that keeps legal/regulatory uncertainty around 340B implementation and potential margin headwinds in some states. AbbVie Loses Challenge in Tennessee

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.